---
title: "iX Biopharma Wins Conditional SGX Nod for New Share Placement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284790085.md"
description: "iX Biopharma Ltd. has received conditional approval from the Singapore Exchange for the issuance of 1,349,434 new ordinary shares under proposed placements to Anson Properties Pte. Ltd. and certain directors. This approval is contingent upon shareholder endorsement at an extraordinary general meeting on May 8, 2026. The placements aim to strengthen the company's capital base, with further announcements expected as developments occur. The current analyst rating for iX Biopharma is a Buy, with a price target of S$1.00."
datetime: "2026-04-30T14:11:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284790085.md)
  - [en](https://longbridge.com/en/news/284790085.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284790085.md)
---

# iX Biopharma Wins Conditional SGX Nod for New Share Placement

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

iX Biopharma Ltd. ( (SG:42C) ) has shared an announcement.

iX Biopharma has received a listing and quotation notice from the Singapore Exchange for 1,349,434 new ordinary shares to be issued under proposed placements to Anson Properties Pte. Ltd. and certain directors. The approval is conditional on shareholders endorsing the placements at an extraordinary general meeting on 8 May 2026 and the company complying with SGX listing requirements.

The proposed share placements, comprising subscription shares and directors’ shares, are intended to be listed and quoted on the SGX-ST once conditions are met, but the notice does not represent an assessment of their investment merits. The move signals the company’s intention to strengthen its capital base with participation from both an external investor and insiders, and further announcements will follow as material developments arise.

The most recent analyst rating on (SG:42C) stock is a Buy with a S$1.00 price target. To see the full list of analyst forecasts on iX Biopharma Ltd. stock, see the SG:42C Stock Forecast page.

**More about iX Biopharma Ltd.**

iX Biopharma Ltd. is a Singapore-incorporated company in the biopharmaceutical sector, focused on developing and commercialising drug products and related technologies. Listed on the Singapore Exchange, it operates through subsidiaries and accesses capital markets to support its growth and ongoing operations.

**Average Trading Volume:** 19,260,576

**Technical Sentiment Signal:** Buy

**Current Market Cap:** S$388.8M

### Related Stocks

- [42C.SG](https://longbridge.com/en/quote/42C.SG.md)
- [9Q9R.SG](https://longbridge.com/en/quote/9Q9R.SG.md)
- [WG9R.SG](https://longbridge.com/en/quote/WG9R.SG.md)

## Related News & Research

- [09:30 ETZifo Now Partners with 7 of the Top 15 Global Biopharma Companies to Unblock the CMC Process Data Pipeline](https://longbridge.com/en/news/285952644.md)
- [Breton Technology takes minority stake in Shanghai photoelectric firm via connected deal](https://longbridge.com/en/news/286127286.md)
- [08:28 ETDrugBank Launches Advisory Board to Guide AI Adoption in Biopharma](https://longbridge.com/en/news/286099221.md)
- [Biocon Reshapes Board and Governance as It Integrates with Biocon Biologics](https://longbridge.com/en/news/285642030.md)
- [Orix Corp Ads (NYSE:IX) Issues Quarterly Earnings Results](https://longbridge.com/en/news/285959337.md)